UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. __)
BIOCRYST PHARMACEUTICALS, INC.
--------------------------------------------------------------------------------
(Name of Issuer)
Common Stock, par value $0.01 per share
--------------------------------------------------------------------------------
(Title of Class of Securities)
09058V-10-3
----------------------------------------------------------------------
(CUSIP Number)
Leo Kirby
667 Madison Avenue, 19th Floor
New York, NY 10021
(212) 521-2418
--------------------------------------------------------------------------------
(Name, Address and Telephone Number of Person Authorized to Receive Notices and
Communications)
October 5, 2005
----------------------------------------------------------------------
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition that is the subject of this Schedule 13D, and is filing this
schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following
box.|X|
Note: Schedules filed in paper format shall include a signed original and five
copies of the schedule, including all exhibits. See Rule 13d-7 for other parties
to whom copies are to be sent.
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 (the "Act") or otherwise subject to the liabilities of that section of the
Act but shall be subject to all other provisions of the Act (however, see the
Notes).
Page 1 of 8
SCHEDULE 13D
----------------------------------------- --------------------------------
CUSIP No. 09058V-10-3 Page 2 of 8 Pages
------------------------ ------- -------
----------------------------------------- --------------------------------
--------- ----------------------------------------------------------------------
1 NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS
Julian C. Baker
--------- ----------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(a) |X|
(b) |_|
--------- ----------------------------------------------------------------------
3 SEC USE ONLY
--------- ----------------------------------------------------------------------
SOURCE OF FUNDS (See Instructions)
4
WC
--------- ----------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
ITEMS 2(d) OR 2(e)
--------- ----------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
United States
--------- ----------------------------------------------------------------------
NUMBER OF 7 SOLE VOTING POWER
SHARES
BENEFICIALLY 0
OWNED BY ------- ----------------------------------------------
EACH 8 SHARED VOTING POWER
REPORTING
PERSON 2,344,036
WITH ------- ----------------------------------------------
SOLE DISPOSITIVE POWER
9
0
------- ----------------------------------------------
SHARED DISPOSITIVE POWER
10
2,344,036
--------- ----------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,344,036
--------- ----------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
(See Instructions) |_|
--------- ----------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
9.0%
--------- ----------------------------------------------------------------------
TYPE OF REPORTING PERSON (See Instructions)
14
IN
--------- ----------------------------------------------------------------------
Page 2 of 8
SCHEDULE 13D
----------------------------------------- --------------------------------
CUSIP No. 09058V-10-3 Page 3 of 8 Pages
------------------------ ------- -------
----------------------------------------- --------------------------------
--------- ----------------------------------------------------------------------
1 NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS
Felix J. Baker
--------- ----------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(a) |X|
(b) |_|
--------- ----------------------------------------------------------------------
3 SEC USE ONLY
--------- ----------------------------------------------------------------------
SOURCE OF FUNDS (See Instructions)
4
WC
--------- ----------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
ITEMS 2(d) OR 2(e) |_|
--------- ----------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
United States
--------- ----------------------------------------------------------------------
NUMBER OF 7 SOLE VOTING POWER
SHARES
BENEFICIALLY 0
OWNED BY ------- ----------------------------------------------
EACH 8 SHARED VOTING POWER
REPORTING
PERSON 2,344,036
WITH ------- ----------------------------------------------
SOLE DISPOSITIVE POWER
9
0
------- ----------------------------------------------
SHARED DISPOSITIVE POWER
10
2,344,036
--------- ----------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,344,036
--------- ----------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
(See Instructions) |_|
--------- ----------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
9.0%
--------- ----------------------------------------------------------------------
TYPE OF REPORTING PERSON (See Instructions)
14
IN
--------- ----------------------------------------------------------------------
Page 3 of 8
Item 1. Security and Issuer.
This statement on Schedule 13D relates to the common stock,
$0.01 par value (the "Common Stock"), of Biocryst Pharmaceuticals Inc, a
Delaware corporation (the "Company"), whose principal executive offices are
located at 2190 Parkway Lake Drive, Birmingham, Alabama 35244.
Item 2. Identity and Background.
This statement is being filed by Julian C. Baker and Felix J.
Baker (each, a "Reporting Person"), each of whom is a United States citizen. Set
forth below is certain information with respect to each Reporting Person:
Name Business Address Present Principal Occupation
---- ---------------- ----------------------------
Julian C. Baker 667 Madison Avenue Managing Member, Baker Bros. Advisors,
New York, NY 10021 LLC (an entity engaged in investment
activities)
Felix J. Baker 667 Madison Avenue Managing Member, Baker Bros. Advisors,
New York, NY 10021 LLC (an entity engaged in investment
activities)
During the last five years, none of the Reporting Persons has
been convicted in any criminal proceeding (excluding traffic violations or
similar misdemeanors) or has been a party to a civil proceeding of a judicial or
administrative body of competent jurisdiction resulting in his being subject to
a judgment, decree or final order enjoining future violations of, or prohibiting
or mandating activities subject to, federal or state securities laws, or finding
any violations with respect to such laws.
Item 3. Source and Amount of Funds or Other Consideration.
The funds used to purchase the shares of Common Stock reported
in Item 5 below were provided from the available working capital of the entities
there indicated.
Item 4. Purpose of Transaction.
The entities referred to in Item 5 below acquired the shares
of Common Stock set forth therein solely for investment. The Reporting Persons
expect to review from time to time the investment positions of these entities
and may, depending on market and other conditions, increase or decrease their
holdings.
Page 4 of 8
Whether the entities purchase any additional shares of Common
Stock or dispose of any shares of Common Stock, and the amount and timing of any
such transactions, will depend upon the Reporting Persons' continuing
assessments of pertinent factors, including the availability of shares of Common
Stock for purchase at particular price levels, the Company's business and
prospects, other business investment opportunities, economic conditions, stock
market conditions, money market conditions, the attitudes and actions of the
Board of Directors and management of the Company, the availability and nature of
opportunities to dispose of shares in the Company and other plans and
requirements of the particular entities. Depending upon their assessments of
these factors from time to time, the Reporting Persons may change their present
intentions as stated above, including determining to acquire additional shares
of Common Stock (by means of open market or privately negotiated purchases) or
to dispose of some or all of the shares of Common Stock under their control. The
Reporting Persons do not have any plans or proposals with respect to any
extraordinary corporate transaction involving the Company or any sale of its
assets or any change in its Board of Directors, management, capitalization,
dividend strategy, charter or by-laws, or any other change in its business or
corporate structure or with respect to the delisting or deregistration of any of
its securities including, without limitation, those matters described in
subparagraphs (a) though (j) of Item 4 of Schedule 13D.
Stephen R. Biggar, an employee of Baker Bros. Advisors, LLC,
is a Director of the Company.
Item 5. Interest in Securities of the Issuer.
Set forth in the table below is the aggregate number of shares
of Common Stock beneficially owned as of the date hereof by each of the
following, together with the percentage of outstanding shares of Common Stock
that such number represents based upon 26,172,526 shares outstanding as of
October 5, according to information furnished to the Reporting Persons by the
Issuer.
Percent of Class
Name Number of Shares Outstanding
---- ---------------- -----------
Baker/Tisch Investments, L.P. 57,993 0.2%
Baker Bros. Investments, L.P. 71,265 0.3%
Baker Bros. Investments II, L.P. 68,671 0.3%
Baker Biotech Fund I, L.P. 703,394 2.7%
Baker Biotech Fund II, L.P. 642,854 2.5%
Baker Biotech Fund II (Z), L.P. 88,865 0.3%
Baker Biotech Fund III, L.P. 557,560 2.1%
Baker Biotech Fund III (Z), L.P. 108,997 0.4%
14159, L.P. 44,437 0.2%
----------- ------
Total 2,344,036 9.0%
Page 5 of 8
By virtue of their ownership of entities that have the power
to control the investment decisions of the limited partnerships listed in the
table above, Julian C. Baker and Felix J. Baker may each be deemed to be
beneficial owners of shares owned by such entities and may be deemed to have
shared power to vote or direct the vote of and shared power to dispose or direct
the disposition of such securities.
Item 6. Contracts, Arrangements, Understandings or Relationships with
Respect to Securities of the Issuer.
Except as reported herein, neither of the Reporting Persons
has any express contracts, arrangements or understandings with any other
Reporting Person with respect to the securities of the Company. Except as set
forth in Item 7 below, none of the Reporting Persons has any contracts,
arrangements, understandings or relationships with the Company.
Item 7. Material to Be Filed as Exhibits.
Exhibit 1. Agreement regarding the joint filing of this statement.
Page 6 of 8
SIGNATURE
After reasonable inquiry and to the best of my knowledge and
belief, I certify that the information set forth in this statement is true,
complete and correct.
October 13, 2005
By: /s/ Julian C. Baker
------------------------------
Julian C. Baker
By: /s/ Felix J. Baker
------------------------------
Felix J. Baker
Page 7 of 8